MSB 3.21% $1.13 mesoblast limited

Ann: Mesoblast Update on Chronic Low Back Pain Program, page-194

  1. 11,472 Posts.
    lightbulb Created with Sketch. 511
    SurgCentre as a part owner of the tech participating in any trial presented to fda for approval.

    Ethical concerns, imo.

    Didn't think it was cryptic?

    As I posted earlier in day thinking it's more likely Surgcentre management maybe behind pressure to get moving and forced SI to seek out Grundenthol to change agreement to get things moving.

    Thinking Surgcentre more interested in earning cash in timely manner from approved product which in itself would be fantastic for Msb going it alone. Imo.
    Last edited by eyeswideopen: 01/07/21
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.